SCHEMBL17822211

SCHEMBL17822211

Cc1c(CN2CCN(S(C)(=O)=O)CC2)sc2c(N3CCOCC3)nc(Br)cc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 17/20 0.59
PIK3CD O00329 12/20 0.59
PIK3CB P42338 12/20 0.59
PIK3CG P48736 10/20 0.59
MTOR P42345 6/20 0.59
RPTOR Q8N122 1/20 0.59
MLST8 Q9BVC4 1/20 0.59
PIK3R1 P27986 4/20 0.56
PIK3C2A O00443 1/20 0.49
PLK4 O00444 1/20 0.49
PIK3R2 O00459 1/20 0.49
PIK3C2B O00750 1/20 0.49
GAK O14976 1/20 0.49
EPHB6 O15197 1/20 0.49
DAPK3 O43293 1/20 0.49
STK16 O75716 1/20 0.49
PIK3C2G O75747 1/20 0.49
NTRK1 P04629 1/20 0.49
NQO2 P16083 1/20 0.49
CSNK2A2 P19784 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29959335 0.82 PIK3CA (0.72) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL17822206 0.82 PIK3CA (0.72) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL19564906 0.82 PIK3CA (0.55) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL17834982 0.82 PIK3CA (0.68) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL29959501 0.82 PIK3CA (0.68) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
Hydrochloric Acid SCHEMBL17822195 0.82 PIK3CA (0.71) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL17822198 0.81 PIK3CA (0.57) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL17822217 0.80 PIK3CA (0.69) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL19549648 0.80 PIK3CA (0.65) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
Water SCHEMBL27149496 0.80 PIK3CA (0.69) PIK3CAPIK3CDPIK3CBPIK3CGMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230289-B1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LTD (IN) 2019-08-14 EP claimed
US-10106554-B2 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs NATCO PHARMA LIMITED (IN) 2018-10-23 US claimed
US-20170320891-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LIMITED (IN) 2017-11-09 US claimed
EP-3230289-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS Natco Pharma Limited (IN) 2017-10-18 EP claimed
WO-2016092556-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LIMITED (IN) 2016-06-16 WO claimed
EP-4326276-A1 IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES Natco Pharma Ltd (IN) 2024-02-28 EP disclosed
CN-117529325-A Improved process for preparing 7- (morpholinyl) -2- (N-piperazinyl) methylthio [2,3-c ] pyridine derivatives 纳特科药品有限公司 2024-02-06 CN disclosed
WO-2022224267-A1 IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES NATCO PHARMA LIMITED (IN) 2022-10-27 WO disclosed
EP-3230289-B1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LTD (IN) 2019-08-14 EP disclosed
US-20170320891-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LIMITED (IN) 2017-11-09 US disclosed
US-20170320891-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LIMITED (IN) 2017-11-09 US disclosed
WO-2016092556-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LIMITED (IN) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106554-B2 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs PRMT7, CDK7, CASP7 PIK3CA 1853/4885PIK3CD 2109/4885PIK3CB 2087/4885
US-20170320891-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS PRMT7, CDK7, CASP7 PIK3CA 1853/4885PIK3CD 2109/4885PIK3CB 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.